CTRI/2021/07/034692已完成1 期
A phase I, prospective, open label, multiple dose study of ZYIL1 administered via oral route to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics in healthy adult subjects
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Healthy male or non-lactating non-pregnant female between 18 and 55 years of age at the time of signing the informed consent form (ICF). (Both inclusive).
- •2.Body mass index of 18.5 to 30.0 kg/m2 (Both inclusive) with a body weight of 50 to 100 kg (Both inclusive).
- •3.Normal QTc interval at screening and Check In [QTcF ââ?°Â¤450 ms]
- •4.Male subjects must agree to use adequate contraception methods during the study and be willing and able to continue contraception for 90 days after administration of study treatment.
- •5.Capable of giving written informed consent, which includes compliance with the study procedures, restrictions, and requirements listed in the protocol.
- •6.Subjects who, in the opinion of the Investigator, are healthy as determined by their pre study medical history, clinical examination, 12-lead ECG and clinical laboratory tests within the institutional normal range or judged as not clinically significant by the Investigator, including the following parameters: hematology, serum biochemistry, urinalysis, and serology.
- •7.Female subjects with history of sterility or at least 1 year menopause or use of long acting non hormonal contraceptive measures (e.g., intrauterine device) and be willing and able to continue contraception for 90 days after administration of study treatment.
排除标准
- •1.History or presence of alcoholism or drug abuse within the past 1 year.
- •2.Presence or history of any of the following disorders/disease within the past 3 months, that might have impact on the clinical trial as per the investigator discretion: cardiovascular, cerebrovascular, dermatological, gastrointestinal, gynecological, hematological, hepatic, malignancy, metabolic, musculoskeletal, neurological, urological, psychiatric, renal, respiratory, venereal, any other major disorders
- •3.History of clinically significant hypersensitivity, intolerance, or allergies, as determined by the Investigator.
- •4.History of COVID-19 infection within 14 days or contact with a confirmed active COVID-19 positive patient within 14 days; or positive COVID-19 test within 5 days of Check-in. .
- •5.History or presence of smoking or consumption of tobacco/nicotine products within the past 1 year.
- •6.Difficulty with donating blood.
- •7.Systolic blood pressure more than 140 mmHg or less than 100 mmHg or diastolic blood pressure more than 90 mmHg or less than 60 mmHg.
- •8.Pulse rate less than 55/minute or more than 100/minute.
- •9.Any clinically significant laboratory or ECG findings during screening
- •10.Surgery within last 3 months or planned major surgery within next 3 months from the date of screening (other than minor cosmetic surgery and minor dental surgery).
- •11.Subjects who have recent illness (eg, fever) within 14 days of check-in
- •12.Volunteers who have participated in any drug research study within past 3 months.
- •13.Volunteers who have donated one unit (350 ml) of blood in the past 3 months.
- •14.Has used prescription drugs and other substances (eg, dietary or herbal supplements such as St Johnââ?¬•s Wort) known to be either significant enzyme inducers or enzyme inhibitors within 4 weeks of Day 1, or use of grapefruit or similar substances (Seville oranges or marmalade, grapefruit juice, grapefruit hybrids, pomelos, exotic citrus fruits or fruit juices) within 7 days of Day 1.
- •15.Use of any over-the-counter (OTC), any prescription medications or alternative tradition of medicine (herbal medicines, homoeopathy, Siddha, Unani, etc.) within the 15 days or 5 half-lives (whichever is longer), prior to receiving study drug that might have impact on the clinical trial as per the investigator discretion.
- •16.A positive urine drugs of abuse test or positive alcohol test at check-in.
- •17.History of, or positive screening test for, hepatitis C infection (defined as positive for hepatitis C virus antibody), hepatitis B infection (defined as positive for hepatitis B surface antigen), or human immunodeficiency virus I or II.
- •18.Any disorder that, in the Investigatorââ?¬•s opinion, may interfere with study compliance, such as significant mental, nervous disorder or other illness. In making this assessment, the Investigator must refer to the study information provided including the Investigatorââ?¬•s Brochure.
- •19.Inability to be venipuncture or tolerate venous puncture.
- •20.Any condition or abnormal baseline findings that in the Investigatorââ?¬•s judgment might increase the risk to the subject or decrease the chance of obtaining satisfactory data needed to obtain the objective of the study.
- •21.Other unspecified reasons that, in the opinion of the Investigator or the Sponsor, make the subject u
研究者
相似试验
未知
1 期
A Phase I, Open-label, Multiple-dose, Dose-escalation Study To Assess the Safety and Tolerability of AZD8931 Monotherapy in Japanese Patients With Advanced Solid Malignancies and in Combination With Paclitaxel in Japanese Female Patients With Advanced Breast CancerJPRN-jRCT2080220921AstraZeneca
已完成
1 期
A phase I study to measure the absorption of cannabidiol (CBD) in healthy volunteers after consumption of an oral CBD soft-gel capsuleNeurological - Other neurological disordersInsomniaACTRN12621001181897Avecho Biotechnology16
已完成
1 期
A Phase I, open label, randomised, single dose, two-way crossover study to determine the pharmacokinetics of two transdermal oxymorphone patch formulations.To promote pain relief, tested in healthy volunteers.Anaesthesiology - Pain managementACTRN12614000613606Phosphagenics Limited15
进行中（未招募）
1 期
A study to compare how much of divarasib is absorbed after a single oral dose of two different tablet formulations in healthy participantsISRCTN16486589Genentech18
进行中（未招募）
1 期
An early stage study looking at how much betrixaban gets into the blood of young people after they take a single capsule, and to see if it is safe to do so.Pediatric patients who are assessed to be at risk for Venous thromboembolism (VTE) but does not require immediate anticoagulant therapy, for example:a. Has previous thrombosis and completed a course of anti-coagulant therapy, and is considered to have a risk for recurrence of VTE, orb. Has any stable disease with a risk for arterial or venous thrombotic disorder, orc. Has any functional CVAD (Central Venous Access Device) in the upper or lower venous system.MedDRA version: 20.0Level: PTClassification code 10053468Term: Anticoagulant therapySystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2018-002562-40-GBPortola Pharma UK Ltd33